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Peptide arrayUp-regulation of Hsp20 protein levels in response to amyloid ﬁbril formation is considered a key protective re-
sponse against the onset of Alzheimer's disease (AD). Indeed, the physical interaction between Hsp20 and Aβ
is known to prevent Aβ oligomerisation and protects neuronal cells from Aβmediated toxicity, however, details
of the molecular mechanism and regulatory cell signalling events behind this process have remained elusive.
Using both conventional MTT end-point assays and novel real time measurement of cell impedance, we show
that Hsp20 protects human neuroblastoma SH-SY5Y cells from the neurotoxic effects of Aβ. In an attempt to pro-
vide a mechanism for the neuroprotection afforded by Hsp20, we used peptide array, co-immunoprecipitation
analysis and NMR techniques to map the interaction between Hsp20 and Aβ and report a binding mode where
Hsp20 binds adjacent to the oligomerisation domain of Aβ, preventing aggregation. The Hsp20/Aβ interaction
is enhanced by Hsp20 phosphorylation, which serves to increase association with lowmolecular weight Aβ spe-
cies and decrease the effective concentration of Hsp20 required to disrupt the formation of amyloid oligomers.
Finally, using a novel ﬂuorescent assay for the real time evaluation of morphology-speciﬁc Aβ aggregation, we
show that phospho-dependency of this effect is more pronounced for ﬁbrils than for globular Aβ forms and
that 25mers corresponding to the Hsp20 N-terminal can be used as Aβ aggregate inhibitors. Our report is the
ﬁrst to provide a molecular model for the Hsp20/Aβ complex and the ﬁrst to suggest that modulation of the
cAMP/cGMP pathways could be a novel route to enhance Hsp20-mediated attenuation of Aβ ﬁbril neurotoxicity.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).Introduction
One of the pathological hallmarks of Alzheimer's disease (AD) is the
extracellular disposition of amyloid-like ﬁlaments that form neuritic
plaques in the brain. The principle component of amyloid plaques is a
small peptide knownas amyloid-β (Aβ),which is derived from sequential
proteolytic cleavage of the amyloid precursor protein (APP) (Hardy and
Selkoe, 2002). Increases in Aβ levels following an imbalance between
the rates of production and clearance of the peptide, promote Aβ
oligomerisation and lead to the formation of both insoluble ﬁbrillar de-
posits and solubleAβ oligomers. Both types ofAβoligomers promoteneu-
ronal dysfunction and cell death leading to neurodegeneration (Harrison
et al., 2007). This series of events is described as the “amyloid cascade hy-
pothesis” and is supported by a wealth of biochemical and genetic data,
though recent failures of a number of anti-Aβ aggregation drugs have
cast some doubt on the hypothesis (Reitz, 2012). The most abundanton-Link Building, University of
illie).
. This is an open access article underpeptide fragment found in AD is Aβ1–40, which accounts for approximate-
ly 90% of amyloid plaques, whereas the remaining 10% is made up of the
more amyloidogenic fragment Aβ1–42. These short peptides are unstable
and readily aggregate to formﬁbrils and a variety of other aggregated spe-
cies that have been shown to be highly cytotoxic (Morgan et al., 2004).
Small Heat Shock Proteins (sHsps) are a group of ATP-independent
chaperones that can prevent the aggregation of mis-folded proteins
and as such, are protective against a number of protein aggregation dis-
eases (Eyles and Gierasch, 2010). This is particularly evident in the ﬁeld
of neurological disease where sHsp proteins have been shown to have a
protective role against Alzheimer's, Parkinson's and Huntington's dis-
eases (reviewed in (Brownell et al., 2012)). One of the ten known
sHsps, Hsp20, has been speciﬁcally linked with AD as it associates
with pathological lesions in diseased brains (Wilhelmus et al., 2006a).
These included senile plaques (SP) and cerebral amyloid angiopathies
(CAA) both of which consist mainly of aggregated Aβ (Wilhelmus
et al., 2009). Expression of Hsp20 has also been observed in reactive as-
trocytes andmicroglia found surrounding both SP and CAA (Wilhelmus
et al., 2006a). The co-localisation of Hsp20 with Aβ aggregates within
AD brain tissue suggests that Hsp20 may represent an endogenousthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1.Mapping the interaction betweenHsp20 and Aβ1–42. Peptide arraywas used tomap
the domains responsible for Hsp20/Aβ1–42 interaction. (A)Diagram of domain structure of
Hsp20 highlighting the PKA/PKG site located in the N-terminal domain and the conserved
α-crystallin domain located between residues 70 and 144. (B) Peptide array libraries of
Hsp20 25mers were probed with either Aβ1–42 or Aβscr. (C) Alanine scanning arrays of
peptide 3 (W11–E35) were probed with either Aβ1–42 (middle panel) or Aβscr (upper
panel) to determine the Hsp20 amino acids that are essential for Aβ1–42 binding. The asso-
ciation of Aβ1–42 with substitution arrays in which serine 16 was replaced by a phospho-
serine or phospho-mimetic substitution (serine changed to aspartic acid) was also evalu-
ated (lower panel). * = p b 0.05, ** = p b 0.01 using Student-t-test (n = 4).
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oligomerisation. Indeed, the physical interaction between Hsp20 and
Aβ has been reported to prevent Aβ oligomerisation (Lee et al., 2006;
Wilhelmus et al., 2006b) and protectmodel cell lines from Aβmediated
toxicity (Lee et al., 2006;Wilhelmus et al., 2006b), however, the molec-
ular nature of this interaction has remained a mystery. Using peptide
array technology (Frank, 2002), we havemapped the sites of interaction
on both Hsp20 and Aβ and in doing so, can now shed light on themech-
anism behind the unique ability of Hsp20 to regulate the aggregation of
Aβ. We report that the PKA/PKG consensus site (RRAS) on Hsp20 is a
key regulator of the chaperone's avidity for Aβ1–42 and directs associa-
tion of the chaperone to structural elements of the peptide in order to
prevent accumulation of neurotoxic Aβ species in SH-SY5Y cells. This
data suggests that the cAMP/cGMP signalling pathway can “switch on”
protection against Aβ-induced cell death and we propose that this
novel signalling axis represents a therapeutic target for the reduction
of Aβ associated neurodegeneration.
Results
Mapping the interaction between Hsp20 and Aβ1–42 using peptide array
As the interaction between Hsp20 and Aβ1–42 had previously been
shown (Lee et al., 2006; Wilhelmus et al., 2006b), we decided to use
synthetic peptide array technology to map the interaction domains be-
tween Hsp20 and Aβ1–42. We have recently used this technique to suc-
cessfully characterize the molecular interactions that underpin two
other protein complexes that include Hsp20; Hsp20–PDE4 (Sin et al.,
2011) and Hsp20–AKAP Lbc (Edwards et al., 2012b). Peptide arrays of
overlapping 25-mer peptides, sequentially shifted by 5 amino acids
and spanning the entire sequence of Hsp20 (domain structure depicted
in Fig. 1A) were incubatedwith Aβ1–42 or a scrambled version of Aβ1–42
(Aβscr). The array was developed using antibodies against Aβ1–42 to
identify the Hsp20 25mers that were able to capture Aβ1–42. Dark
spots represent positive areas of Aβ1–42 interaction whereas clear
spots are negative for the association (Fig. 1B).Whilst no signal was ob-
servedwhen the arrayswere incubatedwith Aβscr, positive signalswere
obtained for Hsp20 derived 25mer peptides 1,2 and 3 following incuba-
tion with Aβ1–42 (Fig. 1B). Peptides 1,2 and 3 span the amino acid se-
quence M1–E35 within the N-terminal domain of Hsp20 (Fig. 1A),
which contains the PKA consensus site at serine 16 (Fan et al., 2004).
pt?>To gain insight into which amino acids within Hsp20 might be criti-
cal in binding to Aβ1–42, we focused on theW11–E35 region of Hsp20 and
using a ‘parent’ 25-mer peptide, generated 25 progeny of this peptide
where each amino acid was sequentially mutated to alanine (or to aspar-
tate if the residue is alanine) to provide an alanine-scanning array
(Fig. 1C). The resulting library of peptides was probed with Aβ1–42
(Fig. 1C:middle panel) or Aβscr (Fig. 1C: upper panel). This identiﬁed a re-
gion of Hsp20 likely to be important for association with Aβ1–42, namely
the double arginine (R13, R14) that forms part of the PKA consensus
(RRASA). As this result suggested that the phosphorylation of serine 16
may inﬂuence the association of Hsp20 with Aβ1–42, we included either
a phospho-serine 16 residue or a phospho-mimic substitution (S to D)
(Fig. 1C, lower panels) into the Hsp2011–35 peptide. Signiﬁcantly more
Aβ1–42 bound to the 25mers that included the phospho-serine 16 residue
or phospho-mimic substitution when compared to the native sequence.
In an attempt to determine the sites on Aβ1–42 that interact with
Hsp20, we constructed peptide arrays of Aβ1–42 and overlaid these
with puriﬁed His-tagged Hsp20 or as a control, puriﬁed His-tagged
RACK1 (Fig. 2A), an unrelated scaffold protein. Strong association of
Hsp20 (but not RACK1) to the ﬁrst 3 spots of the Aβ1–42 array
(representing amino acids 1–35) was observed. Alanine scanning analy-
sis of the ﬁrst 25 amino acids of Aβ1–42 (Fig. 2B) showed that the tri-
peptide spanning H14,Q15 and K16 was critical for Hsp20 binding
(Fig. 2C). Interestingly, this region abridges the K16LVFF20 oligomerisation
domain of Aβ1–42. This region is knownas the pathogenic aggregation siteof the peptide and is essential for the formation of beta-sheets and
amyloidogenicity (Hilbich et al., 1992; Tjernberg et al., 1996). Taken
together (Figs. 1 and 2), our peptide array data suggest a mechanism
where phospho-Hsp20 binds avidly to Aβ1–42 and prevents self-
association of the peptide.
Hsp20—mediated prevention of cellular Aβ1–42 toxicity
To determine whether the ability of Hsp20 to protect neuronal cells
is enhanced following phosphorylation at serine 16, we set up an MTT
viability assay using undifferentiated SH-SY5Y cells (Fig. 3A). As expect-
ed, addition of Aβ1–42 but not Aβscr, resulted in a signiﬁcant ($ = p b
0.001) reduction in cell viability when compared with vehicle only
control (Fig. 3A). The Aβ1–42-mediated reduction in cell viability was
signiﬁcantly reduced in cells that had been transfected with Hsp20
wild type or the phospho-mimic Hsp20 (S16D), but not the phospho-
null Hsp20 mutant (S16A). (* = p b 0.05: comparing Aβ1–42 treated,
transfected cells with Aβ1–42 treatedmock transfected cells) suggesting
that phosphorylation enhanced Hsp20 protection against Aβ1–42. Al-
though the MTT assay is the most common means of assessing Aβ1–42
toxicity in neuronal cells (Lee et al., 2006; Datki et al., 2003), the assay
is limited by its sensitivity (Mozes et al., 2012), lack of ability to detect
neuroprotective effects (Lobner, 2000) and by the fact that it is an end-
point assay that supplies limited information about the temporal nature
Fig. 2.Mapping the interaction between Aβ1–42 and Hsp20. (A) Diagram of the of Aβ1–42 peptide with oligomerisation domain highlighted. Peptide array libraries of 25mers that spanned
the Aβ1–42 sequencewere probedwith either His-Hsp20 orHis-RACK1. (B) Alanine scanning arrays of Aβ1–42 peptide 1 (D1–G25)were probedwith either His-Hsp20 (upper panel) or His-
RACK1 (lower panel) to determine the Aβ1–42 amino acids that are essential for Hsp20 binding. (C) Quantiﬁcations of spot density of peptides in B (typical of n = 3).
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sensitive, real time, non-invasive measurement of neuronal cell growth
has become increasingly popular. This technique has been shown to be
an accurate and reliablemethod bywhich to decipher the kinetics of cell
death in neuronal cultures (Diemert et al., 2012; Mosse et al., 2008),
something that cannot be achieved using discontinuous methods such
as MTT. Brieﬂy, neuronal cells are cultured in 96-well plates that have
a network of micro-electrodes in the base and changes in adherence,
proliferation or cell morphology can be distinguished by the impedance
readout (Xiao et al., 2002a; Xiao et al., 2002b) which is measured in ar-
bitrary units called “Cell Index”. Comparing the toxicity dose response of
Aβ1–42 in SH-SY5Y neuroblastoma cells (Fig. 3B) it was apparent that
impedance was a more sensitive readout of cell viability than MTT, es-
pecially at Aβ1–42 concentrations of 5 μM and above (Fig. 3B). Analysis
of SH-SY5Y growth curves over 48 h showed that cells were unaffected
by Aβscr, and proliferated at a constant rate over the time period
(Fig. 4A). Addition of Aβ1–42, however, resulted in normal growth for
the ﬁrst 6 h, followed by a constant reduction in the cell index
(Fig. 4A) that is characteristic of cell death (Diemert et al., 2012). Trans-
fection of HSP20 into SH-SY5Y cells delayed the toxic effect of Aβ1–42
and slowed the decrease in cell index (Fig. 4B).
When this experiment was repeated with increasing amounts of
Aβ1–42, transfection of HSP20 caused a signiﬁcant right shift of the cell
index dose response curve (Fig. 5A left panel), again signifying that
Hsp20 could protect against amyloid toxicity. It is noteworthy that the
levels of phospho-HSP20, as well as exogenous HSP20, were elevated
in these cells (Fig. 5A, right panel). To further investigate whether
HSP20 phosphorylation had a bearing on Aβ1–42 toxicity, SH-SY5Ycells were transfected with HSP20 wild type, the phospho-mimic
HSP20 (S16D), the phospho-null Hsp20 mutant (S16A) or vector alone
(control) (Fig. 5B right panel). As expected, all transfected cells were
unaffected by Aβscr, and grew at a constant rate (Fig. 5B left panel).
Transfection of all the HSP20 species, however, signiﬁcantly increased
cell index when compared to control after 48 h (Fig. 5C left and right
panels) of Aβ1–42 treatment.
Hsp20 phosphorylation alters the ability to affect morphology of Aβ
aggregates
Using a novel assay for the evaluation of Aβ1–42 aggregate formation
(Quinn et al., 2014), we tested whether the phosphorylation state of
Hsp20 at serine 16 impacted the chaperone's ability to prevent the
oligomerisation of Aβ1–42. The assay relies on ﬂuorescence self-
quenching between Aβ1–42 peptides labelled at the N-terminal position
with HiLyte Fluor 555 (Aβ555). Basically, amyloid self-assembly brings
the covalently attachedﬂuorescence dyes into close proximity to induce
aﬂuorescence quenchingprocess that can be used tomonitor the aggre-
gation process in real time (Garai and Frieden, 2013). Here, we have
used this method to investigate the inhibitory properties of Hsp20
against Aβ1–42 aggregation. We explored the ﬂuorescence response of
Aβ555 in the presence of Hsp20 at experimental conditions known to
promote different morphologies. For instance, it has been shown that
low concentrations of 1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP) (1–4%
v/v) promote the formation of ring-like and globular structures, whilst
ﬁbril-like morphologies are formed in the presence of physiological
(150 mM) concentrations of NaCl at 37 °C. We have observed a
Fig. 3. Cell viability assays to monitor Aβ1–42 mediated cytotoxicity. (A) The MTT cell via-
bility assay was used to determine the effect of Aβ1–42 or Aβscr on cell viability of SH-SY5Y
cells transfected with various constructs of Hsp20 (see inset for relative levels of expres-
sion). ($ = p b 0.001). Signiﬁcant reduction in viability is denoted by * = p b 0.05
and $ = p b 0.001 using Student-t-test (n = 4). (B) Direct comparison of Aβ1–42 dose-
dependent reduction in SH-SY5Y cell viability measured byMTT or using the xCELLigence
real-time monitoring system. Data representative of n = 3.
Fig. 4. Real time monitoring of Aβ1–42 induced cytotoxicity in SH-SY5Y cells. (A) Imped-
ance growth proﬁles of SH-SY5Y cells were measured over 48 h following treatment
with Aβ1–42 or Aβscr .(B) Impedance growth proﬁles of SH-SY5Y cells transfected with
empty vector or Hsp20 (see inset for relative expression levels) were measured over 48
h following treatment with Aβ1–42.
49R.T. Cameron et al. / Molecular and Cellular Neuroscience 61 (2014) 46–55pronounced difference in the effect of wild type Hsp20 to the amyloid
aggregation process under both experimental conditions suggesting a
certain degree of morphology-speciﬁcity for the interaction of Hsp20
and amyloid aggregates.
In the absence of Hsp20, the addition of 1.5% of HFIP to a freshly pre-
parednon-aggregated solution of 0.3 μMAβ555 in 50mMTris-HCl buffer
(pH 7.9) induced a 62± 3% decrease in ﬂuorescence intensity (Fig. 6A)
and 25 ± 2% under ﬁbril-growing conditions (Fig. 6C). When the same
experiments were repeated in the presence of Hsp20-WT, we observed
a signiﬁcant inhibition of amyloid growth under ﬁbril-like conditions
when using a molar excess of Hsp20-WT (i.e., 1:2 molar ratio Aβ:
Hsp20), with the efﬁciency of the self-quenching process decreasing
by 4-fold from 25 ± 2 to 4 ± 2% (Fig. 6B). In contrast, little inhibition
was detected under HFIP-induced aggregation, or under any experi-
mental conditions, when using a 4:1 molar excess of Aβ over Hsp20
(Fig. 6A and B). To get further insights into the mechanistic details of
Hsp20 modulation of amyloid aggregation, we next repeated the ﬂuo-
rescence quenching assays using several relevant Hsp20 variants
including S16D, RRA binding mutant and the P20L polymorph (a natu-
rally occurringmutant that is known to affect itsHsp20 secondary struc-
ture and reduce its capacity to be phosphorylated at serine 16 (Nicolaou
et al., 2008)).
The phospho-mimetic variant S16D exhibited higher inhibition efﬁ-
ciency (~50%) of globular- (Fig. 6A) and ﬁbril-like (Fig. 6B) structures
than the wild type, even at Aβ:S16D molar ratios (4:1) where Hsp20-
WT showed no signiﬁcant inhibitory effect. Interestingly, higher con-
centrations of S16D (1:2 Aβ:S16D molar ratio) had only a marginal ef-
fect in the ﬂuorescence quenching accompanying the formation of
globular structures (b10% decrease in quenching). In contrast, theinhibition of ﬁbrils was strongly increased as reﬂected by the relative
decrease in ﬂuorescence quenching from 11 ± 2% (4:1 Aβ:S16D molar
ratio) to a practically undetectable level (3 ± 2%) when using a 1:2
molar ratio (Aβ:S16D) (Fig. 6B). In agreement with our peptide array
data, these results conﬁrm that replacing serine 16 with aspartic
acid promotes the Hsp20/Aβ interaction and decreases the effective
concentration of Hsp20 required to disrupt the formation of amyloid ag-
gregates. This effect beingmore pronounced for ﬁbrils than for globular-
forming conditions. For the RRA and P20L variants the variation in
ﬂuorescence self-quenching showed also a remarkable dependence
with the type of aggregate and the Aβ:Hsp20 variant molar ratio. P20L
failed to inhibit the formation of globular structures at bothmolar ratios
investigated (Fig. 6A). In fact, we observed a signiﬁcant increase in ﬂuo-
rescence quenching from 62 ± 3% in the absence of P20L to values of
86± 1% and 75± 2% at 4:1 and 1:2 (Aβ:P20L) molar ratios, respective-
ly. In contrast, P20L was able to inhibit the formation of ﬁbrillar struc-
tures (Fig. 6B), although its efﬁciency at the highest molar ratio was
lower (~9 ± 4% self-quenching efﬁciency) than for the RRA and S16D
variants (~3%). For the RRA mutant, the behaviour under ﬁbril-like
forming conditions is parallel to that observed for S16D (Fig. 6B), whilst
its ability to disrupt the formation of globules was slightly lower than
for S16D at similar molar ratios (Fig. 6A).
We next performed similar experiments, but using 25-mer peptide
analogues of Hsp20 sequences that include the Hsp20/Aβ interaction
motifs identiﬁed from peptide array studies (Figs. 1 and 2). We used
Hsp20-WT, the S16D and RRA variants (Fig. 6C and D). The most signif-
icant differences between experiments using full length proteins and
peptide analogues can be described as follows: i) the 25-mer S16D var-
iant is approximately 2-fold less efﬁcient in disrupting the formation of
ﬁbrils and globular structures than the full-length form and ii) whilst
the full-length Hsp20 RRA mutant protein was capable of efﬁciently
inhibiting the formation of ﬁbrillar structures, the 25-mer version of
Fig. 5.Hsp20 over-expression attenuates Aβ1–42 induced cytotoxicity in SH-SY5Y cells. (A) A dose response curve of cell viability (asmeasured by cell index) was constructed over a range
of Aβ1–42 concentrations in SH-SY5Y cells transfected with empty vector or Hsp20. Relative levels of phospho-Hsp20 and total Hsp20 were determined by western blotting (left panels).
Impedance growth proﬁles of SH-SY5Y cells transfected with empty vector, Hsp20Wt, Hsp20S16D, and Hsp20S16A (see inset for relative expression levels) were measured over 48 h
following treatment with (B) Aβscr or (C) Aβ1–42. Quantiﬁcations of cell index at 48 h compared with the scrambled control in (A) were determined (n= 3) and statistical evaluation un-
dertaken * = p b 0.05 and *** = p b 0.001 using Student-t-test.
50 R.T. Cameron et al. / Molecular and Cellular Neuroscience 61 (2014) 46–55the RRA variant was unable to do so at both molar ratios. Actually, we
observed a very pronounced and reproducible increase in ﬂuorescence
self-quenching (~64 ± 10%) with the 25-mer RRA at 4:1 molar ratio
compared to the control experiment in the absence of RRA (25 ± 2 5),
indicative of higher levels of aggregation. When a 1:2 molar ratio of
Aβ:Hsp20was used, the ﬂuorescence self-quenching returned to values
similar to those obtained in the absence of RRA (Fig. 6D).Nuclear magnetic resonance spectroscopy to monitor Aβ1–40 aggregation
To support the data from the ﬂuorescence self-quenching assay
(Fig. 6) and peptide array experiments (Fig. 2), we undertook conven-
tional NMR spectroscopic analysis to examine the effect of Hsp20 on
the oligomerisation of synthetic 15N-labelled Aβ1–40 peptide. Small
changes in chemical shifts were detectable across all residues compared
Fig. 6. Evaluation of morphology-speciﬁc inhibition of Aβ1–42 aggregation by Hsp20 using a novel ﬂuorescence self-quenching assay. The interaction between Hsp20 variants and Aβ1–42
labelled at the N-terminus with HiLyte Fluor 555 (Aβ555) was monitored using ﬂuorescence self-quenching under globular (A) and ﬁbrillar (C) growing conditions. The interaction be-
tween Hsp20 N-terminal 25mers and Aβ1–42 labelled at the N-terminus with HiLyte Fluor 555 (Aβ555) was monitored using ﬂuorescence self-quenching under globular (B) and ﬁbrillar
(D) growing conditions. WT=wild type Hsp20, S16D= a phosphomimetic HSP20, RRA= a construct that is defective in binding Aβ1–42, and P20L= a polymorph (a naturally occurring
mutant that is known to reduce the capacity of Hsp20 to be phosphorylated at serine 16).
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the region proximal to the oligomerisation domain (KLVFF), spanning
the sequence H13HQKL17, which includes the same region identiﬁed in
the peptide array experiments (Fig. 7B). Hsp20-RRA induced the largest
changes in chemical shift for residues within this region, whilst Hsp20-
S16D increased the shift distance across 80% of the assigned residues
relative Hsp20-WT. Following initial 1D 1H NMR and 2D 15N-HSQC
spectral analysis, each samplewas incubated in conditions that promote
oligomerisation of 15N-Aβ1–40. Samples were then re-analysed in order
to determine howmuch 15N-Aβ1–40 peptide would still be visible in so-
lution given that aggregated species larger than 50 kDa are not detected
using NMR spectroscopy (Kwan et al., 2011). As expected the 15N-
Aβ1–40 only control had signiﬁcantly reduced peak intensities suggest-
ing reduced concentration of monomeric Aβ peptide via increased ag-
gregation (compare Suppl Fig. 1A and Suppl Fig. 1B). The same was
also true for the 15N-Aβ1–40 peptide co-incubated with the bindingmu-
tant Hsp20-RRA although to a lesser extent. However, both the Hsp20-
WT and the Hsp20-S16D co-incubations maintained signiﬁcantly more
15N-Aβ1–40 in its monomeric form when compared to both 15N-Aβ1–40
control and Hsp20-RRA (Suppl. Fig. 1A and B). In order to conﬁrm that
any loss in signalwas the result of Aβ1–40 aggregation andnot proteolyt-
ic degradation, theNMR sampleswere blotted for Aβ (Fig. 7C left panel).
As expected, the levels of monomeric Aβ1–40 had virtually disappearedin the 15N-Aβ1–40 only control sample (lane 1) whereas monomeric
and low molecular weight species were most prominent in Aβ samples
that had been incubated with His-Hsp20-S16D (lane 3) followed by
those that had been incubatedwithHis-Hsp20-WT. In contrast, Aβ sam-
ples that contained His-Hsp20-RRA, exhibited no detectable levels of
monomeric Aβ1–40 in solution and greatly reduced levels of lowmolec-
ular weight species between 10 and 25 kDa (lane 4). To determine the
nature of the Aβ1–40 aggregates that associates with Hsp20 under the
conditions used for NMR studies, immunoprecipitates of Hsp20 were
probed with an antibody against Aβ (Fig. 7C, right panel). In agreement
with the notion that phosphorylation of Hsp20 at serine 16 increases
the association of the chaperone with Aβ, Hsp20-S16D was able to
pull-down more monomeric Aβ1–40 than the WT variant (lane 2 vs
lane 3). Interestingly, Hsp20-S16D was also able to coIP an Aβ1–40 spe-
cies around the size expected for Aβ tetramers (16 kDa) (Fig. 7C, right
panel). This Aβ species was not detected in the Hsp20-WT IP despite
there being species of this size in solutionwithHsp20-WTpost aggrega-
tion (Fig. 7C left panel). Despite similar levels of Hsp20-RRA precipitat-
ing with the His-agarose beads (data not shown), there was no low
molecular weight Aβ1–40 species detected in the Hsp20 IP (Fig. 7C,
right panel, lane 4).
Taken together, the data in Fig. 7 suggests that Hsp20 interacts with
Aβ1–40 and prevents it from aggregating into higher molecular weight
52 R.T. Cameron et al. / Molecular and Cellular Neuroscience 61 (2014) 46–55oligomers, even at a molar ratios of 1:4 (Hsp20:Aβ). Both Hsp20-WT
and -S16D maintained signiﬁcantly more LMW species of Aβ1–40 in so-
lution than the Aβ1–40 only control. The interaction between all Hsp20
variants and Aβ1–40 was strongest at domains important for beta-
sheet formation and oligomerisation of Aβ. Finally, the introduction of
the phospho-mimetic S16D increased the chemical shifts at a number
of residues and maintained the Aβ1–40 peptide in its non-toxic, random
coil conformationmore so thanHsp20-WT. These data validate theﬁnd-
ings from the array data that suggest the phosphorylation of Hsp20 en-
hances its interaction with Aβ to inhibit amyloidogenesis.
Discussion
Small heat-shock proteins have been shown for some time to have
the capacity to bind Aβ peptides and inhibit aggregation and subse-
quent cytotoxicity in vitro (Kudva et al., 1997; Lee et al., 2006). In
particular, Hsp20 has been shown to interactwith soluble Aβ and inhib-
it its aggregation and routes of enhancing the interaction between
sHSPs and Aβ has been identiﬁed as a potential therapeutic strategy
(Wilhelmus et al., 2006b). In this report, we have for the ﬁrst time, dis-
covered a molecular mechanism by which the interaction between Aβ
and Hsp20 may be regulated in SH-SY5Y neuroblastoma cells. Impor-
tantly, the phosphorylation of Hsp20 at serine 16 by PKA/G is known
to induce the protective abilities of Hsp20 in a number of physiological
processes associated with diseases of the heart (Edwards et al., 2012a;
Fan and Kranias, 2011), however, the data presented here also describes
a novel neuroprotective role for Hsp20phosphorylation. In short, PKA/G
phosphorylation of the chaperone enhances its association with Aβ
(Figs. 1 and 7C) on amotif that is proximal to theAβ oligomerisation do-
main K16L17V18F19F20 (Figs. 2, 7A, B), which is necessary for the assem-
bly of toxic aggregates (Beyreuther et al., 1992; Watanabe et al., 2001).
This action serves to reduce the formation of higher order Aβ oligomers
(Figs. 6, and 7C), by inhibiting Aβ aggregation directly at the site of
oligomerisation, to protect neuroblastoma cells from the cytotoxic ef-
fects of Aβ (Figs. 3, 4 and 5).We propose that the positively charged res-
idue of the Aβ oligomerisation domain, K16 (the only residue in the
sequence essential for mediating binding of Hsp20, Fig. 2) forms a
charge interaction with Hsp20 following the introduction of a negative-
ly charged phosphate group at serine 16. It is noteworthy that the Aβ
residue, K16, plays an important role in the non-amyloidogenic process-
ing of APP, asα-secretase cleavage at this site does not generate the Aβ
peptide (Zheng and Koo, 2006). The scanning array (Fig. 2) and NMR
analysis (Fig. 7) also demonstrated that H14 and Q15 are important res-
idues that mediate the binding of Hsp20. H14 has been shown to play an
important role in the co-ordination of metal ion binding, such as zinc,
and copper (Diaz et al., 2006). Such metal ions can have signiﬁcant ef-
fect on aggregation propensity of Aβ (Olofsson et al., 2009). Interesting-
ly, we also saw a reduction in binding when the Aβ glutamic acid
residue (E22) was substituted for alanine (Fig. 2). Mutation of this resi-
due causes severe early onset familial AD (Selkoe and Podlisny, 2002)
resulting from an increased capacity to form ﬁbrils when compared
with wild type Aβ (Inayathullah and Teplow, 2011). This is particularly
true of the ‘Dutch’ mutation (E22Q) (Levy et al., 1990) and the ‘Arctic’
mutation (E693G) (Nilsberth et al., 2001). It is possible that sub-
optimal binding of Hsp20 to Aβ because of such mutations decreases
the neuro-protective capacity of Hsp20 and promotes the onset of AD.
Early structural characterisation of Aβ1–40 in solution using NMR
spectroscopy has shown that when in solution Aβ1–40 contains two he-
lical regions spanning Q15–D23 and I31–M35, with the rest of the peptide
adopting a random coil formation (Sticht et al., 1995). Our initialFig. 7. Chemical shift analysis of 15N-Aβ1–40 co-incubationwithHsp20.A. 2DHSQCexperiment s
ple) or Hsp20-RAA (red) at 4 °C prior to aggregation. B. Chemical shift perturbation plot from s
precipitations from the NMR samples were probed for Aβ following 4 day incubation under ag
construct that is defective in binding Aβ1–42. For interpretation of the references to colour in thanalysis of the chemical shift perturbations for all Hsp20 variants was
most pronounced in these two helical regions and more importantly,
we demonstrated that the introduction of the phospho-mimetic substi-
tution (S16D) increased the shift difference in the large majority of res-
idues relative to Hsp20-WT, suggesting that the introduction of a
negative charge at serine 16 increases the interaction of Hsp20 with
Aβ1–40. Greater shift differences between Hsp20-WT and -S16D were
also detected in the region spanning residues G29–V36 which span the
second helical region and suggest that phosphorylation of Hsp20 en-
hances its interaction with the both helical regions within Aβ1–40 in
order to maintain it in its soluble conformation. Crucially, both of
these regions interact with each other upon structural conversion into
insoluble ﬁbrils and current models show that the two regions fold
into a β-strand-turn-β-strand conversion. This step is the primary nu-
cleation event of β-sheet secondary structure, which is essential for ﬁ-
brillar growth (Ahmed et al., 2010).
Rather unexpectedly, we found that the RRA ‘binding mutant’ in-
duced themost pronounced changes in shift distance across all residues
within Aβ1–40. This was most pronounced at the oligomerisation do-
main, particularly at residuesH13 andH14 and is likely due to the remov-
al of the two adjacent, positively charged arginine residues, removing
the charge repulsion thatwould normally occur at the two histidine res-
idues. Despite the Hsp20-RRA mutant inducing the biggest change in
chemical shifts, this did not translate into increased aggregation inhibi-
tion, relative to Hsp20-WT and -S16D. Both Hsp20-WT and S16Dmain-
tained signiﬁcant amounts of Aβ1–40 in solution in its monomeric
conformation despite incubation under conditions that promote Aβ ag-
gregation. The conformational transition of Aβ from random coil to α-
helix to β-sheet structures is a key step in promoting neurotoxicity of
the peptide (Simmons et al., 1994), therefore it appears that chaperone
activity of Hsp20 functions to stabilise Aβ in a non-toxic conformation.
Additionally, analysis of the in vitro pull-down assay with Hsp20-
S16D and Aβ1–40 following aggregation (Fig. 7C), revealed distinct low
molecular weight species at 17 kDa and 27 kDa that have previously
been described as being neurotoxic (Lambert et al., 1998). This suggests
that phospho-Hsp20 has a higher propensity to bind soluble toxic spe-
cies relative to WT, a ﬁnding that was in agreement with data from a
novel Aβ aggregation assay, where both full length Hsp20 protein and
25mer peptides spanning the N-terminal of Hsp20 and containing the
S16D mutation were able to inhibit ﬁbrillar growth. Interestingly,
transducible phospho-mimetics based on the N-terminal sequence of
Hsp20 have been developed, to combat a number of disease conditions
including, keloid scarring, subarachnoid haemorrhage, and platelet
aggregation (Edwards et al., 2011). Whether such peptides would
have physiological efﬁcacy in reducing ﬁbril formation may be worthy
of further investigation.
In summation, we present a novel, regulatory mechanism by which
Hsp20 attenuates Aβ1–42 cytotoxicity by increasing its ability to inhibit
two morphology distinct Aβ aggregation pathways relevant to physio-
logical amyloidogenesis and early nucleation events. Hsp20 binds di-
rectly to domains involved in the structural conversion to neurotoxic
Aβ species and functions as a chaperone to maintain Aβ in a soluble
non-toxic conformation. Phospho-mimetic Hsp20 also binds to higher
order structures which may represent a mechanism of solubilising hy-
drophobic Aβ1–42 conformations to neutralise toxicity or increase Aβ
peptide clearance. Finally using a novel label-free cellmonitoring system
we were able to conﬁrm that increased intracellular levels of phospho-
Hsp20 protects against cytotoxicity in SH-SY5Y neuroblastoma cells as-
sociated with diffusible Aβ and that this protection is likely mediated
through a direct interaction as opposed to the anti-apoptotic propertieshowing 15N-Aβ1–40 (green); co-incubatedwith either Hsp20WT (blue), Hsp20-S16D (pur-
ame experiment as (A). Data plotted relative to the 15N-Aβ1–40 control. C. Hsp20 immuno-
gregating conditions. WT=wild type Hsp20, S16D= a phosphomimetic HSP20, RRA= a
is ﬁgure legend, the reader is referred to the web version of this article.
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of Hsp20 represents a novel endogenous protection mechanism that
may be targeted therapeutically for the treatment of AD.
Experimental methods
Aβ peptides
For cell-based assays synthetic Aβ peptides were purchased from
rPeptide® (Georgia, USA). Aβ1–42 (A-1002) peptides are the recombinant
form of the human Aβ peptide. Aβ1–42 scrambled peptide (Aβscr) (A-
1004)which is a rearranged version of the peptide that carries the over-
all weight and charge of Aβ1–42, was used as a control. Peptides were
dissolved in DMSO at a concentration of 5 mg/ml and sonicated in a
water bath for 15 min. Samples were aliquoted and stored at−20 °C
until required. To create neurotoxic Aβ1–42 derivatives the method of
Lambert et al. was used (Lambert et al., 1998), where Aβ1–42 (or scram-
bled) peptides were brought to 100 μM in cold PBS and incubated at 4–
8 °C for 24 h. The resulting aggregated peptides were added directly to
cell culture medium typically at 1:10 dilution (Aβ:media). Samples
from each 100 μM stock were taken for SDS-PAGE and western blotting
analysis.
For NMR assays 15N uniformly labelled Aβ1–40 (A-1101-2) was also
purchased from rPeptide® (Georgia, USA). In order to fullymonomerise
the peptide it was resuspended in 1% NH4OH and sonicated in a water
bath for 15 min. The peptide concentration was brought to 400 μM
with cold NMR buffer (50 mM NaPi (Na2HPO4) pH 7.5). The peptide
was then dialysed in 4 l of cold NaPi for 2 h to remove NH4OH and
then added directly to Hsp20 containing NaPi buffer for immediate
analysis. Aβ1–40 was maintained below 4 °C in order to reduce
aggregation.
For real-time Aβ1–42 aggregation assays synthetic Aβ1–42 peptides
were purchased from Anaspec Inc. (USA), suspended in 100%
1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP) at 5 mg/ml and incubated
for complete solubilisation at room temperature for 1.5 h. HFIP was
subsequently removed by evaporation under vacuum for 4 h and stored
at−20 °C.
Antibodies
The following antibodies were used in western blotting analysis:
anti-Aβ1–42— Sigma-Aldrich (A8354), anti-Hsp20 — Upstate (07–490),
anti-phospho-S16 Hsp20 — Abcam (ab58522), and alpha tubulin
HRP — Abcam (ab40742). Secondary antibodies used: anti-mouse
HRP — GE Healthcare (NXA931)and anti-rabbit — Sigma-Aldrich
(A6154). For co-IPs: anti-Polyhistidine-agarose — Sigma-Aldrich
(A5713).
His-Hsp20 puriﬁcation
The full length Hsp20 sequence was cloned into a pET28c vector
(Novagen) in order to express an N-terminal His-tag and then trans-
formed into competent BL21 cells (Invitrogen, Paisley). Cells were
grown until OD600 ~ 1, 1 M of IPTG was then added and cells were
grown for a further 24 h at 37 °C. The protein was then puriﬁed using
nickel afﬁnity chromatography. The resulting protein product was
then checked for impurities on a 4–12% gel and then veriﬁed through
western blotting techniques. Subsequent site-directed mutagenesis of
this vector was carried out using Quikchange (Stratech) in accordance
with manufacturer's protocol.
SDS-PAGE & western blotting
SDS-PAGE analysis was done onNuPage® pre-cast gels in Invitrogen
X-cell apparatus (Invitrogen, Paisley) using Laemmli 2× loading buffer
with 5% β-mercaptoethanol. MES-SDS running buffer was used, due tothe low molecular weight of proteins involved. For western blotting
(WB) analysis, samples were transferred using NuPage® X-cell blotting
module onto a nitrocellulose membrane. Membranes were blocked
using 5% milk in 1× TBST (w/v). Antibodies were incubated in 1% milk
in 1× TBST (w/v) for either 1 h at room temperature or overnight at
4 °C. Signals were detected using enhanced chemiluminescence (ECL)
systems and developed on an X-omat ﬁlm developer.
Peptide array
The Hsp20 protein sequence was split into overlapping 25 amino
acid fragments that advanced from the N-terminal to the C-terminal
in increments of 5 residues until the full length of Hsp20 was covered.
Two copies of these Hsp20 25mer libraries were SPOT synthesized
(Frank, 2002) on continuous cellulose membranes using Fmoc-
chemistry with the Autospot-Robot ASS 222 (Intavis Bioanalytical In-
struments AG, Köln, Germany). For the alanine scanning arrays, versions
of Hsp20 25mer (residues 11–36) were synthesised to incorporate ala-
nine residues in place of the endogenous amino acids andwere progres-
sively substituted from the N-terminal to C-terminal. In the event of
alanine being the original residue an aspartic acidwas incorporated. Ad-
ditionally, two spots in Hsp2011–36 modiﬁed to incorporate either a
phospho-serine or a phospho-mimic (aspartic acid) at the Hsp20 phos-
phorylation site (serine 16). Prior to use, the cellulose membrane was
activated using analytical ethanol and then blocked with 5% milk/TBST
(w/v) for 1 h. The Hsp20 arrays were then overlaid with either Aβ1–42
or Aβscr overnight at 4 °C. The arrays were then analysed using WB
techniques. Analogous methods were used to probe overlapping
Aβ1–42 with His-tagged HSP20 in order to determine which domains
within Aβ1–42 are responsible for binding.
Cell culture
Undifferentiated SH-SY5Y cells were grown in Dulbecco's Modiﬁed
Eagle's Medium (DMEM) and F12-Ham's at a 1:1 ratio, media were
supplemented with 10% (v/v) foetal bovine serum (FBS), 1% (v/v)
L-GLUTAMINE, 1% (v/v) Minimum Essential Medium — with non-
essential amino acids (MEM-NAA) and 1% (v/v) Pen/strep. Cells were
cultured in a humidiﬁed, 5% (v/v) CO2, 37 °C incubator.
Aβ toxicity assays
Full-length Hsp20 was cloned into pcDNA3.1/V5-His-TOPO vector
(Invitrogen) and related mutants created using Quikchange (Stratech).
The various Hsp20 constructs and an empty vector control were
electroporated into SH-SY5Y cells using nucleofection kit V (Amaxa)
in accordance with manufacturer's instructions. Cell were seeded at a
density of 5 × 103/well into seeded into 96-well plate forMTT-based as-
says or 96-well E-plate for xCELLigence based assays and left overnight
to allow for cell re-attachment. Remaining cells were seeded into 6 well
plates and harvested after 48 h to conﬁrm expression of the various
Hsp20 constructs. Addition of Aβ peptides and vehicle controls was car-
ried out once cell index reached 1. The xCELLigence SP system (Acea)
was used for real-time monitoring of cell growth for a minimum of 48
h post addition of Aβ peptides. The resulting data was analysed using
(RTCA) real-time cell analyzer software (Roche) and exported to
Excel. MTT based cell viability was carried out in parallel in accordance
with Promega CellTiter 96® non-radioactive cell proliferation assay
(G4000) in accordance with manufacturer's protocols and added 48 h
post addition of Aβ peptides.
Nuclear magnetic resonance spectroscopy
15N-labelled Aβ1–40 samples were combined with 1 mg/ml of vari-
ous His-Hsp20 constructs to give a ﬁnal concentration of 200μM of
55R.T. Cameron et al. / Molecular and Cellular Neuroscience 61 (2014) 46–55Aβ1–40 and 25 μM of Hsp20 (4:1 molar ratio) in 50 mM NaPi buffer,
200 μM Aβ1–40 only was used as a control.
NMR spectra were recorded on Bruker AVANCE 600MHz spectrom-
eter at 4 °C to assess pre-aggregation spectra prior to incubating all sam-
ples at 37 °C for 4 days under agitating conditions (300 rpm). Samples
were then reanalysed at 4 °C to ascertain how much Aβ1–40 peptide
remained in a solution. Following NMR analysis samples were centri-
fuged at 13000 rpm in order to remove insoluble aggregates that had
formed during the aggregation process and supernatant was analysed
using SDS-PAGE and western blotting to ensure any loss of signal was
not due to proteolytic degradation of the 15N-labelled Aβ1–40 peptide.
Supernatants from each sample were then used to undertake co-
immunopuriﬁcation using anti-polyhistidine-agarose conjugated
beads (Sigma-Aldrich, UK). 20 μl of His-agarose beads was added to
500 μl of the Aβ1–40:Hsp20 solutions and incubated at 4 °C overnight
on a rotating wheel. Each sample was then spun at 6000 rpm to isolate
the beads. Following the removal of supernatant beads were subjected
to a further 3 washes in PBS prior to addition of 2 × SDS sample buffer.
Samples were then run on an SDS-PAGE gel to verify the interaction be-
tween Aβ1–40 and Hsp20.
Real-time Aβ aggregation protocol
The real-time aggregation has recently been described by Quinn
et al. (in press).
Statistical analysis
Data is expressed as the means ± SEM. Two group comparisons
were evaluated using two-tailed Student's t-test. Differences were con-
sidered statistically signiﬁcant when p-value was b0.05.
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